Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation

NCT07251673 | Recruiting

• 2 other identifiers: APHP2416852024-A02640-47
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Dravet syndrome with SCN1A gene mutation is a developmental and epileptic encephalopathy characterized by treatment-resistant epilepsy and global developmental delay. Despite the considerable attention recently Dravet syndrome (DS) in drug development, studies characterising the progression of the neurodevelopmental phenotype over time remain limited. In particular, many previous studies of natural history studies have been of short duration or have focused only on a subgroup of the paediatric population. This prospective natural history study is being conducted to define more precisely the neurodevelopmental trajectory of SCN1A-positive Dravet syndrome in patients aged aged 6 months to 21 years with SCN1A mutations. The study will examine these characteristics over a 4-year period using standardised assessments. The study will also explore potential metabolomic biomarkers and their relationship with clinical outcomes.

Conditions

Dravet Syndrome

Keywords

Dravet syndrom; epilepsy

Outcome Measures

Primary Outcomes (1)

• Score of scale Vineland-3

  Change in adaptive function measured by the Vineland-3 over time at 1, 2, 3 and 4 years follow-up (160 is the maximum score and 20 is the minimum score - the higher score is the better outcome)

  Up to 4 years

Secondary Outcomes (5)

• Score of scale Gross Motor Function Measure-66 (GMFM-66)

  Up to 4 years

• Score of scale Bayley-IV sub-domains

  Up to 4 years

• Average Clinical Global Impressions (CGI) scale score at each age

  Up to 4 years

• Score of improvement scale

  Up to 4 years

• Dosage of serum GABA

  Up to 4 years

Study Arms (1)

Dravet syndrom Cohort

Blood sample for metabolomic analysis and scale

Eligibility Criteria

• Age: 6 Months - 21 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Patients aged 6 months to 21 years with Dravet syndrome due to a pathogenic or probably pathogenic variant of the SCN1A

You may qualify if:

• The patient or his/her legal representative must be able to give informed consent for participation in the study.
• The participant or legal representative are able (in the opinion of the investigator) to comply with the research protocol.
• Patient (male/female) between 6 months and 21 years of age inclusive at the time of consent.
• The patient has a confirmed pathogenic or probably pathogenic variant of the SCN1A gene demonstrated by a genetic test.
• The patient had normal development prior to the onset of the first seizure.
• The patient had an onset of epileptic seizures between the ages of 3 and 15 months inclusive.
• The patient is receiving at least one of the following anti-epileptic drugs prior to consent: brivaracetam, clobazam, cannabidiol, fenfluramine, levetiracetam, sodium valproate, stiripentol, topiramate

You may not qualify if:

• The patient has a copy number variation of the SCN1A gene affecting other genes, including a microdeletion of SCN1A.
• The patient has a mutation in the SCN1A gene on both alleles.
• The patient has a known or clinically suspected pathogenic mutation in a gene associated with epilepsy other than the SCN1A gene.
• The patient has a concomitant genetic mutation or clinical comorbidity deemed likely to disrupt the typical phenotype of Dravet syndrome.
• The patient has a known gain-of-function mutation, defined by functional studies, including p.Thr226Met.
• The patient has a history of neurodevelopmental abnormality prior to the onset of seizures, based on the medical record.
• The patient has been seizure free for a period of one year prior to informed consent.
• The patient has, at any time, taken antiepileptic drugs with a worsening effect for 6 consecutive weeks or more, including: carbamazepine, eslicarbazepine, lacosamide, lamotrigine, oxcarbazepine, phenytoin (chronic oral administration), tiagabine and vigabatrin.
• The patient has already received innovative therapies such as antisense ologonucleotides, gene therapy or cell therapy.
• The patient has a structural abnormality on brain imaging (MRI or CT scan) which the principal investigator considers to be an epileptogenic lesion.

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead
• Encoded Therapeutics: collaborator

Study Sites (1)

Robert Debré Hospital

Paris, Ap-hp / DRCI, 75019, France

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

An extra tube of blood taken during a blood test for metabolomics for metabolomic analysis.

MeSH Terms

Conditions

Epilepsies, Myoclonic; Epilepsy

Condition Hierarchy (Ancestors)

Epilepsy, Generalized; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Epileptic Syndromes

Study Officials

• Stéphane Auvin, MD, PhD

  Assistance Publique Hopitaux de Paris

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Stéphane Auvin, MD, PhD

CONTACT

0033140032000; stephane.auvin@aphp.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 19, 2025
• First Posted: November 26, 2025
• Study Start: September 15, 2025
• Primary Completion (Estimated): October 1, 2030
• Study Completion (Estimated): October 1, 2030
• Last Updated: February 3, 2026

Record last verified: 2026-02

Locations

FR (1)